VBIV
VBI Vaccines Inc. [VBIV] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
VBIV Stock Summary
Top 10 Correlated Stocks
VBIV
In the News
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates
VBI Vaccines, Inc. (VBIV) came out with a quarterly loss of $2.43 per share versus the Zacks Consensus Estimate of a loss of $2.27. This compares to loss of $2.40 per share a year ago.
VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans
VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.
VBI Vaccines to focus on hep B treatments, conduct 1-for-30 reverse stock split
VBI Vaccines Inc. VBIV, -0.96% said Tuesday it is planning to focus its efforts on hepatitis B, as part of a reorganization that will see it cut operating costs and headcount by 30% to 35% and conduct a reverse stock split. Cambridge, Mass.
VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Misses Revenue Estimates
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -14.29% and 85.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
VBI Vaccine (VBIV) Inks Deal With Agenus for Brain Cancer Study
VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.
VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook
VBI Vaccines has not been immune to sell-off with their share price shrinking by roughly 75% over the past year despite the company making significant headway both clinically and commercially. VBIV is still in my Compounding Healthcare "Bio Boom" speculative portfolio. The company's efforts in 2022 have fortified that position.
VBI Vaccines (VBIV) Stock: Why It Fell 10.72% After Hours
The stock price of VBI Vaccines (VBIV) fell by 10.72% after hours in the most recent trading session. This is why.
Why Ocugen, Sorrento Therapeutics, and VBI Vaccines Are on the Move Today
Healthcare has become a bona fide stock picker's market this year.
3 Biotech Penny Stocks That Climbed in After-Hours Trading
Check these three biotech penny stocks out for your watchlist right now The post 3 Biotech Penny Stocks That Climbed in After-Hours Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis
VBI Vaccines recently reported updated data from their VBI-1901 candidate in recurrent Glioblastoma. The company publicized the median overall survival and 18-month overall survival data are outperforming historical controls. VBI-1901 is showing its ability to have an impact on the tumor response and clinical outcomes. One patient who is still on protocol has been progression-free for over two years.
VBIV Financial details
VBIV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.05 | 0.56 | 0.15 | 0.07 | 0 | |
| Net income per share | -0.98 | -15.1 | -6.11 | -7.85 | -0.55 | |
| Operating cash flow per share | -0.69 | -12.23 | -6.47 | -4.7 | -0.29 | |
| Free cash flow per share | -0.78 | -13.16 | -6.6 | -4.93 | -0.3 | |
| Cash per share | 0.9 | 11.1 | 16.37 | 14.32 | 0.24 | |
| Book value per share | 1.49 | 22.17 | 23.6 | 16.93 | 0.25 | |
| Tangible book value per share | 0.48 | 6.35 | 14.75 | 9.36 | 0.01 | |
| Share holders equity per share | 1.49 | 22.17 | 23.6 | 16.93 | 0.25 | |
| Interest debt per share | 0.26 | 4.49 | 2.83 | 4.3 | 0.22 | |
| Market cap | 3.15B | 164.84M | 600.24M | 596.58M | 3.03B | |
| Enterprise value | 3.11B | 135.47M | 507.36M | 506.68M | 3.02B | |
| P/E ratio | -49.11 | -2.74 | -13.49 | -8.94 | -21.5 | |
| Price to sales ratio | 939.22 | 74.22 | 565.73 | 945.45 | 2.8K | |
| POCF ratio | -69.2 | -3.38 | -12.76 | -14.95 | -41.12 | |
| PFCF ratio | -61.16 | -3.15 | -12.49 | -14.24 | -38.83 | |
| P/B Ratio | 32.11 | 1.87 | 3.5 | 4.15 | 47.23 | |
| PTB ratio | 32.11 | 1.87 | 3.5 | 4.15 | 47.23 | |
| EV to sales | 925.74 | 60.99 | 478.19 | 802.98 | 2.79K | |
| Enterprise value over EBITDA | -52.42 | -2.94 | -11.63 | -7.45 | -36.91 | |
| EV to operating cash flow | -68.21 | -2.78 | -10.78 | -12.7 | -40.98 | |
| EV to free cash flow | -60.28 | -2.59 | -10.56 | -12.09 | -38.7 | |
| Earnings yield | -0.02 | -0.36 | -0.07 | -0.11 | -0.05 | |
| Free cash flow yield | -0.02 | -0.32 | -0.08 | -0.07 | -0.03 | |
| Debt to equity | 0.4 | 0.38 | 0.22 | 0.46 | 1.42 | |
| Debt to assets | 0.29 | 0.28 | 0.18 | 0.32 | 0.59 | |
| Net debt to EBITDA | 0.76 | 0.64 | 2.13 | 1.32 | 0.13 | |
| Current ratio | 2.64 | 1.58 | 7.61 | 4 | 2.1 | |
| Interest coverage | -18.56 | -23.86 | -16.11 | -14.38 | -20.42 | |
| Income quality | 0.72 | 0.89 | 1.02 | 0.57 | 0.65 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 6.2 | 6.34 | 19.46 | 60.75 | 51.87 | |
| Research and developement to revenue | 11.47 | 11.86 | 14 | 31 | 14.33 | |
| Intangibles to total assets | 0.48 | 0.52 | 0.31 | 0.31 | 0.39 | |
| Capex to operating cash flow | 0.13 | 0.08 | 0.02 | 0.05 | 0.06 | |
| Capex to revenue | -1.79 | -1.65 | -0.94 | -3.16 | -4.01 | |
| Capex to depreciation | -11.06 | -3.05 | -0.61 | -1.09 | -2.11 | |
| Stock based compensation to revenue | 0.99 | 1.77 | 4.98 | 15.26 | 8.96 | |
| Graham number | 5.73 | 86.78 | 56.98 | 54.7 | 1.75 | |
| ROIC | -4.68 | -1.76 | -2.33 | 1.74 | -6.04 | |
| Return on tangible assets | -0.9 | -1.01 | -0.31 | -0.46 | -1.49 | |
| Graham Net | 0.31 | 2.75 | 11.35 | 6.66 | -0.1 | |
| Working capital | 38.35M | 17.21M | 114.69M | 97.7M | 40.75M | |
| Tangible asset value | 31.62M | 25.29M | 107.29M | 79.53M | 3.69M | |
| Net current asset value | 22.26M | 13.02M | 94.37M | 63.89M | -13.23M | |
| Invested capital | 0.14 | 0.18 | 0.1 | 0.22 | 0.81 | |
| Average receivables | 99.5K | 128.5K | 139K | 42.5K | 51K | |
| Average payables | 3.93M | 3.59M | 2.43M | 4.01M | 8.63M | |
| Average inventory | 849.5K | 993K | 1.61M | 2.36M | 4.59M | |
| Days sales outstanding | 6.09 | 33.03 | 26.49 | 4.63 | 31.71 | |
| Days payables outstanding | 490.15 | 52.04 | 148.66 | 145.05 | 419.93 | |
| Days of inventory on hand | 73.74 | 49.64 | 85.68 | 87.3 | 213.61 | |
| Receivables turnover | 59.91 | 11.05 | 13.78 | 78.88 | 11.51 | |
| Payables turnover | 0.74 | 7.01 | 2.46 | 2.52 | 0.87 | |
| Inventory turnover | 4.95 | 7.35 | 4.26 | 4.18 | 1.71 | |
| ROE | -0.65 | -0.68 | -0.26 | -0.46 | -2.2 | |
| Capex per share | -0.09 | -0.92 | -0.14 | -0.23 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.01 | 0.04 | 0.04 | 0 | 0.06 | |
| Net income per share | -2.98 | -7.85 | -3.26 | -0.08 | -4.34 | |
| Operating cash flow per share | -2.31 | -2.03 | -2.01 | -0.07 | -2.51 | |
| Free cash flow per share | -2.37 | -2.15 | -2.16 | -0.08 | -2.58 | |
| Cash per share | 11.77 | 9.57 | 9.71 | 0.24 | 4.69 | |
| Book value per share | 15.05 | 12.26 | 9.74 | 0.25 | 5.22 | |
| Tangible book value per share | 7.44 | 4.87 | 2.79 | 0.01 | -1.81 | |
| Share holders equity per share | 15.05 | 12.26 | 9.74 | 0.25 | 5.22 | |
| Interest debt per share | 4 | 4 | 6.18 | 0.21 | 6.3 | |
| Market cap | 428.71M | 208.8M | 182.28M | 3.03B | 78.33M | |
| Enterprise value | 360.76M | 159.73M | 150.63M | 3.02B | 90.31M | |
| P/E ratio | -4.18 | -0.77 | -1.62 | -38.58 | -0.52 | |
| Price to sales ratio | 3.4K | 603.47 | 575.01 | 10.34K | 161.51 | |
| POCF ratio | -21.52 | -11.97 | -10.55 | -159.1 | -3.62 | |
| PFCF ratio | -20.97 | -11.27 | -9.81 | -147.83 | -3.53 | |
| P/B Ratio | 3.31 | 1.98 | 2.17 | 47.23 | 1.74 | |
| PTB ratio | 3.31 | 1.98 | 2.17 | 47.23 | 1.74 | |
| EV to sales | 2.86K | 461.64 | 475.18 | 10.31K | 186.2 | |
| Enterprise value over EBITDA | -23.47 | -7.2 | -7.33 | -148.95 | -4.88 | |
| EV to operating cash flow | -18.11 | -9.15 | -8.72 | -158.55 | -4.17 | |
| EV to free cash flow | -17.65 | -8.62 | -8.11 | -147.32 | -4.07 | |
| Earnings yield | -0.06 | -0.32 | -0.15 | -0.01 | -0.48 | |
| Free cash flow yield | -0.05 | -0.09 | -0.1 | -0.01 | -0.28 | |
| Debt to equity | 0.5 | 0.63 | 1.05 | 1.42 | 1.85 | |
| Debt to assets | 0.33 | 0.39 | 0.51 | 0.59 | 0.65 | |
| Net debt to EBITDA | 4.42 | 2.21 | 1.54 | 0.51 | -0.65 | |
| Current ratio | 3.31 | 2.29 | 2.77 | 2.1 | 1.75 | |
| Interest coverage | -15.65 | -21.21 | -16.95 | -11.57 | -10.1 | |
| Income quality | 0.94 | 0.38 | 0.69 | 0.9 | 0.78 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 86.75 | 43.6 | 44.86 | 54.22 | 0 | |
| Research and developement to revenue | 18.75 | 16.31 | 15.72 | 8.59 | 6.5 | |
| Intangibles to total assets | 0.34 | 0.37 | 0.35 | 0.39 | 0.47 | |
| Capex to operating cash flow | 0.03 | 0.06 | 0.08 | 0.08 | 0.02 | |
| Capex to revenue | -4.09 | -3.11 | -4.1 | -4.96 | -1.1 | |
| Capex to depreciation | -1.09 | -1.99 | -2.47 | -2.79 | -1.05 | |
| Stock based compensation to revenue | 19.86 | 7.1 | 7.61 | 7.94 | 4.15 | |
| Graham number | 31.76 | 46.54 | 26.73 | 0.65 | 22.59 | |
| ROIC | 1.53 | -19.74 | 3.55 | -1.18 | -0.7 | |
| Return on tangible assets | -0.2 | -0.62 | -0.25 | -0.21 | -0.55 | |
| Graham Net | 4.77 | 2.29 | 0.01 | -0.08 | -4.47 | |
| Working capital | 78.36M | 52.22M | 61.54M | 40.75M | 22.26M | |
| Tangible asset value | 64.04M | 41.94M | 23.99M | 3.69M | -15.61M | |
| Net current asset value | 47.91M | 26.15M | 8.02M | -13.23M | -31.6M | |
| Invested capital | 0.26 | 0.32 | 0.62 | 0.81 | 1.16 | |
| Average receivables | 2.16M | 2.66M | 2.47M | 3.3M | 2.81M | |
| Average payables | 4.1M | 4.77M | 8.64M | 12.32M | 11.41M | |
| Average inventory | 3.32M | 4.05M | 4.92M | 6.2M | 6.68M | |
| Days sales outstanding | 2.05K | 636.76 | 704.67 | 1.27K | 275.38 | |
| Days payables outstanding | 128.33 | 200.45 | 392.94 | 350.83 | 248.76 | |
| Days of inventory on hand | 132.58 | 144.53 | 195.22 | 178.46 | 171.15 | |
| Receivables turnover | 0.04 | 0.14 | 0.13 | 0.07 | 0.33 | |
| Payables turnover | 0.7 | 0.45 | 0.23 | 0.26 | 0.36 | |
| Inventory turnover | 0.68 | 0.62 | 0.46 | 0.5 | 0.53 | |
| ROE | -0.2 | -0.64 | -0.33 | -0.31 | -0.83 | |
| Capex per share | -0.06 | -0.13 | -0.15 | -0.01 | -0.06 |
VBIV Frequently Asked Questions
What is VBI Vaccines Inc. stock symbol ?
VBI Vaccines Inc. is a US stock , located in Cambridge of Ma and trading under the symbol VBIV
What is VBI Vaccines Inc. stock quote today ?
VBI Vaccines Inc. stock price is $2.75 today.
Is VBI Vaccines Inc. stock public?
Yes, VBI Vaccines Inc. is a publicly traded company.
Company Profile
- Volume Average 107.74K
- Market Capitalization 24.53M
- Employee 190
- CEO Mr. Jeffery R. Baxter F.C.M.A., FCMA
- Headquarters Cambridge,MA,US
- IPO Date 2001-11-19
-
Website
https://www.vbivaccines.com 
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
